CD28 and neoplasm: Checkpoint blockade targeting the PD-1/PD-L1 axis exerts its immunomodulatory function by alleviating in situ suppression of existing tumour-reactive T cells, as PD-1 signaling impairs both TCR/CD3- and CD28-mediated stimulatory and co-stimulatory signal integration, respectively [164,165].